Comparing adaptive SBRT to standard image-guided SBRT for localized prostate cancer
Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
This study is testing if a new type of targeted radiation therapy for prostate cancer can improve urinary health compared to the standard radiation treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 320 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06825091 on ClinicalTrials.gov |
What this trial studies
The ASPIRE study is a Phase III randomized trial that investigates the effectiveness of adaptive stereotactic body radiotherapy (SBRT) compared to standard image-guided SBRT in patients with localized prostate cancer. This single-center study will enroll 320 participants and aims to determine if adaptive SBRT can enhance urinary outcomes while ensuring effective cancer control. Patients will be randomized into two groups, receiving either adaptive SBRT or standard SBRT, with stratification based on various clinical factors. The study will adhere to established dosing protocols for both treatment arms.
Who should consider this trial
Good fit: Ideal candidates include men over 18 years old diagnosed with localized prostate adenocarcinoma who are eligible for SBRT.
Not a fit: Patients who are planned for elective nodal irradiation or have contraindications to radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved urinary outcomes for patients undergoing treatment for localized prostate cancer.
How similar studies have performed: Other studies have shown promising results with adaptive radiotherapy approaches, suggesting potential benefits in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years 2. Histologic diagnosis of prostate adenocarcinoma 3. Localized prostate cancer 4. Low risk, intermediate risk, or high risk allowed 5. Patient planned for prostate SBRT Exclusion Criteria: 1. Planned for elective nodal irradiation 2. Contraindications to radiotherapy
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Center — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Rachel Glicksman, MD
- Email: rachel.glicksman@uhn.ca
- Phone: 416-946-4559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.